1st Quarter - Report

AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS for AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS

Firm
Client
Income
—
Expenses
$200,276
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

FDA: Adverse event collection workshop and comments. Comments on FDA Science and Technology Report. Standard setting for pharmaceutical supply chain issues including radio frequency identification.

LobbyistCovered position, as disclosed
JUSTINE COFFEY —
JOSEPH M HILL —
BRIAN M MEYER —
GERALYN TRUJILLO New —

Contacted: Health Resources & Services Administration (HRSA); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; SENATE; Food & Drug Administration (FDA)

Medicare/Medicaid MMM

Ambulatory Payment Classification (APC) Panel testimony and comments. APC Panel Nomination. Letters to CMS and CMS officials regarding compendia additions and deletions including American Hospital Formulary Service-Drug Information. Comments relating to electronic prescribing under Part D. HR 3025, Medicare Prescription Drug Savings for our Seniors Act of 2007 and S1827, Pharmacist Access and Recognition in Medicare (PhARM) Act of 2007; provisions relating to medication therapy management. HR 3162, Children's Health and Medicare Protection Act (CHAMP Act), provisions on comparative effectiveness research. Recognition of pharmacists as health care providers and payment for clinical services. Recognition of AHFS as drug compendia for coverage of unlabeled uses. Funding for specialized pharmacy residency programs. Electronic prescribing.

LobbyistCovered position, as disclosed
JUSTINE COFFEY —
JOSEPH M HILL —
BRIAN M MEYER —
GERALYN TRUJILLO New —

Contacted: Health Resources & Services Administration (HRSA); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE; Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 3162 (110th), H.R. 3025 (110th)

Pharmacy PHA

Health Services and Resources Administration 340 B drug pricing program; proposed guidance on definition of patient, contract pharmacy and participation by children's hospitals. HR 3580, Food and Drug Administration Amendments Act of 2007, titles 8 and 9, all provisins. S.901. Reauthorization of National Health Service Corps. Provisions relating to loan forgiveness programs. Funding for Food and Drug Administration. HR 1956, Patient Protection and Innovative Biologic Medicines Act of 2007 and HR 1038, Access to Life Saving Medicine Act, HR 5629, Pathway for Biosimilars Act, provisions dealing with interchangability. HR 5491, Pharmacy Technician Training and Registration Act of 2008, all provisions. Proposal by FDA for a behind the counter drug category (public meeting and comments). Distribution of patient information and medication guides. Pharmacologic class in patient information. Proposal to transition Mevacor from prescription to over the counter status.

LobbyistCovered position, as disclosed
JUSTINE COFFEY —
JOSEPH M HILL —
BRIAN M MEYER —
GERALYN TRUJILLO New —

Contacted: Health Resources & Services Administration (HRSA); Centers For Medicare and Medicaid Services (CMS); SENATE; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA)

Bills named: H.R. 3580 (110th), H.R. 1956 (110th), H.R. 5491 (110th), H.R. 5629 (110th), H.R. 1038 (110th), S. 901 (110th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.